Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

ZHANG Xia-hua, GONG Shou-jun, WU Zheng. The clinical therapeutic outcomes of Yigankang in treatment of chronic hepatitis B patients[J]. Journal of Pharmaceutical Practice and Service, 2004, (3): 148-149.
Citation: ZHANG Xia-hua, GONG Shou-jun, WU Zheng. The clinical therapeutic outcomes of Yigankang in treatment of chronic hepatitis B patients[J]. Journal of Pharmaceutical Practice and Service, 2004, (3): 148-149.

The clinical therapeutic outcomes of Yigankang in treatment of chronic hepatitis B patients

  • Received Date: 2003-11-26
  • Objective To evaluate the clinical therapeutic outcomes of Yigankang in treatment chronic hepatitis B patients.Methods 31 patients with HBeAg(+),HBV-DNA(+)were treated by routine therapy with Yigankang for 3 months,and 25 patients as control were investigated meantime.Results The serum HBeAg negative conversion rate was 35.5% and the serum HBV-DNA negative was 45.1% after treatment.The serum HBeAg and HBeAb conversion rate was 29%.Conclusion Yigankang can improve the liver function of chronic hepatitis B,and it can eliminate HBV.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(1922) PDF downloads(949) Cited by()

Related
Proportional views

The clinical therapeutic outcomes of Yigankang in treatment of chronic hepatitis B patients

Abstract: Objective To evaluate the clinical therapeutic outcomes of Yigankang in treatment chronic hepatitis B patients.Methods 31 patients with HBeAg(+),HBV-DNA(+)were treated by routine therapy with Yigankang for 3 months,and 25 patients as control were investigated meantime.Results The serum HBeAg negative conversion rate was 35.5% and the serum HBV-DNA negative was 45.1% after treatment.The serum HBeAg and HBeAb conversion rate was 29%.Conclusion Yigankang can improve the liver function of chronic hepatitis B,and it can eliminate HBV.

ZHANG Xia-hua, GONG Shou-jun, WU Zheng. The clinical therapeutic outcomes of Yigankang in treatment of chronic hepatitis B patients[J]. Journal of Pharmaceutical Practice and Service, 2004, (3): 148-149.
Citation: ZHANG Xia-hua, GONG Shou-jun, WU Zheng. The clinical therapeutic outcomes of Yigankang in treatment of chronic hepatitis B patients[J]. Journal of Pharmaceutical Practice and Service, 2004, (3): 148-149.

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return